Claudio Morales-Perez, a protein production scientist at Generate:Biomedicines, with one of the company's four cryogenic electron microscopes (Studio Nouveau, Lara Woolfson)

Ex­clu­sive: The se­cret to de­sign­ing pro­tein drugs with AI? Gen­er­ate be­lieves it's cryo-EM at un­prece­dent­ed scale

One of the lead­ing biotech com­pa­nies us­ing ar­ti­fi­cial in­tel­li­gence to de­sign pro­tein-based drugs is bet­ting that suc­cess lies not in more com­put­ing pow­er, but in gen­er­at­ing new lab­o­ra­to­ry da­ta to feed back in­to its al­go­rithms.

To gain that edge, Gen­er­ate:Bio­med­i­cines has in­vest­ed more than $30 mil­lion in a new­ly re­fur­bished lab in An­dover, MA, in­clud­ing near­ly $15 mil­lion on four high-pow­ered cryo­genic elec­tron mi­cro­scopes — a quan­ti­ty prac­ti­cal­ly un­heard of for the pricey tools.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.